174 related articles for article (PubMed ID: 33613520)
1. The Protective HIV-1 Envelope gp41 Antigen P1 Acts as a Mucosal Adjuvant Stimulating the Innate Immunity.
Xu L; Tudor D; Bomsel M
Front Immunol; 2020; 11():599278. PubMed ID: 33613520
[TBL] [Abstract][Full Text] [Related]
2. Thymic stromal lymphopoietin (TSLP) acts as a potent mucosal adjuvant for HIV-1 gp140 vaccination in mice.
Van Roey GA; Arias MA; Tregoning JS; Rowe G; Shattock RJ
Eur J Immunol; 2012 Feb; 42(2):353-63. PubMed ID: 22057556
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 12 and innate molecules for enhanced mucosal immunity.
Boyaka PN; Lillard JW; McGhee J
Immunol Res; 1999; 20(3):207-17. PubMed ID: 10741861
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
5. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
[TBL] [Abstract][Full Text] [Related]
6. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.
Verma V; Tan W; Puth S; Cho KO; Lee SE; Rhee JH
J Transl Med; 2016 May; 14(1):135. PubMed ID: 27184355
[TBL] [Abstract][Full Text] [Related]
7. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
[TBL] [Abstract][Full Text] [Related]
8. Oral vaccination with influenza hemagglutinin combined with human pulmonary surfactant-mimicking synthetic adjuvant SF-10 induces efficient local and systemic immunity compared with nasal and subcutaneous vaccination and provides protective immunity in mice.
Kimoto T; Kim H; Sakai S; Takahashi E; Kido H
Vaccine; 2019 Jan; 37(4):612-622. PubMed ID: 30553569
[TBL] [Abstract][Full Text] [Related]
9. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
[TBL] [Abstract][Full Text] [Related]
10. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.
Boyaka PN; Tafaro A; Fischer R; Fujihashi K; Jirillo E; McGhee JR
Curr Pharm Des; 2003; 9(24):1965-72. PubMed ID: 12871182
[TBL] [Abstract][Full Text] [Related]
12. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
14. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.
Sasaki S; Sumino K; Hamajima K; Fukushima J; Ishii N; Kawamoto S; Mohri H; Kensil CR; Okuda K
J Virol; 1998 Jun; 72(6):4931-9. PubMed ID: 9573261
[TBL] [Abstract][Full Text] [Related]
15. TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
McKay PF; King DF; Mann JF; Barinaga G; Carter D; Shattock RJ
PLoS One; 2016; 11(2):e0148984. PubMed ID: 26862758
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Innate Immunity by lignin-Carbohydrate, a Novel TLR4 Ligand, Results in Augmentation of Mucosal IgA and Systemic IgG Production.
Tsuji R; Ikado K; Fujiwara D
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29278400
[TBL] [Abstract][Full Text] [Related]
17. New generation of mucosal adjuvants for the induction of protective immunity.
Yuki Y; Kiyono H
Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
[TBL] [Abstract][Full Text] [Related]
18. A novel strategy for inducing enhanced mucosal HIV-1 antibody responses in an anti-inflammatory environment.
Wegmann F; Krashias G; Lühn K; Laamanen K; Vieira S; Jeffs SA; Shattock RJ; Sattentau QJ
PLoS One; 2011 Jan; 6(1):e15861. PubMed ID: 21253014
[TBL] [Abstract][Full Text] [Related]
19. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization.
Staats HF; Bradney CP; Gwinn WM; Jackson SS; Sempowski GD; Liao HX; Letvin NL; Haynes BF
J Immunol; 2001 Nov; 167(9):5386-94. PubMed ID: 11673557
[TBL] [Abstract][Full Text] [Related]
20. Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.
Borsutzky S; Fiorelli V; Ebensen T; Tripiciano A; Rharbaoui F; Scoglio A; Link C; Nappi F; Morr M; Buttó S; Cafaro A; Mühlradt PF; Ensoli B; Guzmán CA
Eur J Immunol; 2003 Jun; 33(6):1548-56. PubMed ID: 12778472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
